Stephanie A. Gregory

3.7k total citations · 1 hit paper
104 papers, 2.3k citations indexed

About

Stephanie A. Gregory is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Stephanie A. Gregory has authored 104 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Pathology and Forensic Medicine, 54 papers in Genetics and 32 papers in Oncology. Recurrent topics in Stephanie A. Gregory's work include Lymphoma Diagnosis and Treatment (61 papers), Chronic Lymphocytic Leukemia Research (48 papers) and Viral-associated cancers and disorders (11 papers). Stephanie A. Gregory is often cited by papers focused on Lymphoma Diagnosis and Treatment (61 papers), Chronic Lymphocytic Leukemia Research (48 papers) and Viral-associated cancers and disorders (11 papers). Stephanie A. Gregory collaborates with scholars based in United States, United Kingdom and Canada. Stephanie A. Gregory's co-authors include John P. Leonard, Sven de Vos, Julie M. Vose, Larry D. Cripe, Margaret A. Shipp, Rajni Sinha, Ronald Levy, Ann M. Lowe, Ann S. LaCasce and Jeff P. Sharman and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Stephanie A. Gregory

98 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

2009 590 citations John P. Leonard, Stephanie A. Gregory et al. Blood profile →

Peers

Countries citing papers authored by Stephanie A. Gregory

Since Specialization

Citations

This map shows the geographic impact of Stephanie A. Gregory's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephanie A. Gregory with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephanie A. Gregory more than expected).

Fields of papers citing papers by Stephanie A. Gregory

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephanie A. Gregory. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephanie A. Gregory. The network helps show where Stephanie A. Gregory may publish in the future.

Co-authorship network of co-authors of Stephanie A. Gregory

This figure shows the co-authorship network connecting the top 25 collaborators of Stephanie A. Gregory. A scholar is included among the top collaborators of Stephanie A. Gregory based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephanie A. Gregory. Stephanie A. Gregory is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase 2 study of CHOP-R-14 followed by 90Y-ibritumomab tiuxetan in patients with previously untreated diffuse large B-cell lymphoma 2017 ·Molecular and Clinical Oncology ·Reem Karmali, Melissa L. Larson, Jamile M. Shammo, Stephanie A. Gregory, (unknown), Parameswaran Venugopal	7
2	CHOP Chemotherapy Followed by Tositumomab and Iodine-131 Tositumomab for Previously Untreated Diffuse Large B-cell Lymphoma 2016 ·Clinical Lymphoma Myeloma & Leukemia ·John P. Leonard, Stephanie A. Gregory, Hedy Smith, Thierry Horner, Vanessa C. Williams, (unknown), Thomas S. Lin	2
3	Observing and modeling the influence of layering on bubble trapping in polar firn 2015 ·Journal of Geophysical Research Atmospheres ·L. Mitchell, Christo Buizert, Edward J. Brook, Daniel J. Breton, John M. Fegyveresi, Daniel Baggenstos, Anaïs Orsi, Jeffrey P. Severinghaus, Richard B. Alley, M. R. Albert, Rachael H. Rhodes, (unknown), Michael Sigl, O. J. Maselli, Stephanie A. Gregory, Jinho Ahn	41
4	The impact of microstructure and physical properties on pore close-off at WAIS Divide and Megadunes 2013 ·PhDT ·Stephanie A. Gregory	1
5	CD26 protease inhibition improves functional response of unfractionated cord blood, bone marrow, and mobilized peripheral blood cells to CXCL12/SDF-1 2012 ·Experimental Hematology ·Kent W. Christopherson, (unknown), (unknown), Laura A. Paganessi, Stephanie A. Gregory, Henry C. Fung	10
6	Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report 2011 ·Leukemia & lymphoma ·Thomas E. Witzig, Paul A. S. Fishkin, Leo I. Gordon, Stephanie A. Gregory, Samuel A. Jacobs, Roger M. Macklis, Peter McLaughlin, Oliver W. Press, Andrew D. Zelenetz	25
7	Multicenter Analysis of Elderly Hodgkin Lymphoma (eHL): Outcomes and Prognostic Factors in the Modern Era 2011 ·Blood ·Andrew M. Evens, Irene Helenowski, Chadi Nabhan, Erika Ramsdale, June M. McKoy, Annette K. Larsen, (unknown), Benjamin M. Parsons, Reem Karmali, Britt Hanson, Leo I. Gordon, Scott E. Smith, Stephanie A. Gregory, (unknown), (unknown)	0
8	In vivo expansion of the megakaryocyte progenitor cell population in adult CD26-deficient mice 2011 ·Experimental Hematology ·Shannon Kidd, Carlos E. Bueso‐Ramos, (unknown), Laura A. Paganessi, Lisa Boggio, Henry C. Fung, Stephanie A. Gregory, Kent W. Christopherson	5
9	Bendamustine's Emerging Role in the Management of Lymphoid Malignancies 2011 ·Seminars in Hematology ·Mathias Rummel, Stephanie A. Gregory	31
10	Safety and Efficacy of Combination Therapy with Fludarabine, Mitoxantrone, and Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan and Maintenance Rituximab as Front-Line Therapy for Patients With Follicular or Marginal Zone Lymphoma 2011 ·Clinical Lymphoma Myeloma & Leukemia ·Reem Karmali, Mohamad Kassar, Parameswaran Venugopal, Jamile M. Shammo, Henry C. Fung, Robert Bayer, (unknown), Stephanie A. Gregory	17
11	An Extended Dosing Regimen of Epoetin Alfa 60,000 Units Every 2 Weeks in Anemic Patients with Cancer Receiving Chemotherapy 2007 ·PubMed ·Stephanie A. Gregory, John Xie, (unknown), Denise Williams, Richard C. Woodman, François Wilhelm	1
12	Denileukin Diftitox as Novel Targeted Therapy for Lymphoid Malignancies 2007 ·Cancer Investigation ·Bryan Wong, Stephanie A. Gregory, Nam H. Dang	24
13	Efficacy and Safety of Rituximab Combined with ESHAP Chemotherapy for the Treatment of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma 2007 ·Clinical Lymphoma & Myeloma ·(unknown), Parameswaran Venugopal, Stephanie A. Gregory, (unknown), Elena Bogdanova	15
14	Efficacy of Darbepoetin Alfa in the Treatment of Chemotherapy-Induced Anemia in Non-Hodgkin's Lymphoma 2006 ·PubMed ·Stephanie A. Gregory	8
15	Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma 2006 ·Cancer ·Robert M. Rifkin, Stephanie A. Gregory, Ann Mohrbacher, Mohamad A. Hussein	101
16	Selecting patients for treatment with 90Y ibritumomab tiuxetan (zevalin) 2003 ·Seminars in Oncology ·Stephanie A. Gregory	8
17	Correlation of tumor necrosis factor α (TNFα) with high Caspase 3-like activity in myelodysplastic syndromes 1999 ·Cancer Letters ·Suneel Mundle, (unknown), Ambereen Ali, (unknown), Vilasini Shetty, Parameswaran Venugopal, Stephanie A. Gregory, Azra Raza	53
18	Excessive Proliferation Matched by Excessive Apoptosis in Myelodysplastic Syndromes: The Cause-Effect Relationship 1997 ·Leukemia & lymphoma ·Azra Raza, Sairah Alvi, (unknown), Lambert F. R. Span, Agapi Parcharidou, (unknown), (unknown), Erwin Robin, (unknown), Stephanie A. Gregory	46
19	Normal and aberrant expression of cytokines in neoplastic cells from chronic lymphocytic leukemias 1993 ·Human Immunology ·Janet M.D. Plate, William H. Knospe, Jules E. Harris, Stephanie A. Gregory	9
20	Acute leukemia following treatment of polycythemia vera and essential thrombocythemia with uracil mustard 1988 ·American Journal of Hematology ·(unknown), Stephanie A. Gregory, William H. Knospe	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact